New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
09:14 EDTFIVE, PUBGY, ANF, SHLD, BLDP, PSUN, OMC, AA, TGT, MNKD, YRCW, ICPT, MOn The Fly: Pre-market Movers
HIGHER: Abercrombie & Fitch (ANF), up 15% after company raises FY adjusted EPS view, shares upgraded at Janney Capital. Macy's (M), up 1.2% after upgraded at Goldman... Intercept (ICPT), up 33.5% after price targets raised at Citigroup, BofA/Merrill and Oppenheimer... Omnicom (OMC), up 2% after Reuters reported EU clears merger with Publicis (PUBGY). LOWER: Target (TGT), down 1% after lowering Q4 comparable sales view, disclosing that information from up to 70M guests taken during data breach... Sears (SHLD), down 11% after saying fourth quarter sales-to-date are down 7.6% and projecting fourth quarter and fiscal-2013 losses that were larger-than-expected... Alcoa (AA), down 6.5% after earnings miss expectations... Pacific Sunwear (PSUN), down 18.4% after sales metrics, guidance, downgrade at Janney Capital... Five Below (FIVE), down 9.7% after cutting fourth quarter guidance... YRC Worldwide (YRCW), down 20% after the International Brotherhood of Teamsters announced that employees did not approve the memorandum of understanding extension proposal made by the company... MannKind (MNKD), down 11.6% after announcing tentative date of FDA advisory committee review of Afrezza.
News For TGT;SHLD;M;AA;ANF;ICPT;OMC;PUBGY;YRCW;PSUN;FIVE;MNKD;BLDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 11, 2014
14:52 EDTMMacy's November 57.5 straddle priced for 5.8% move into Q3
12:09 EDTMEarnings Preview: Analyst says Macy's trends decelerated at back-end of Q3
Macy's (M) is scheduled to report third quarter earnings before the market open on Wednesday, November 12, with a conference call scheduled for 10:30 am ET. Macy's is a retailer that sell a range of merchandise, including apparel and accessories, cosmetics, home furnishings and other consumer goods. EXPECTATIONS: Analysts are looking for earnings per share of 50c on revenue of $6.34B, according to First Call. The consensus range for EPS is 46c-55c on revenue of $6.24B-$6.46B. LAST QUARTER: Macy's reported second quarter EPS of 80c on revenue of $6.23B, below estimates for 86c and $6.3B, respectively. Same-store sales, together with comparable sales of departments licensed to third parties, were up 4% from the prior year. Q2 comparable sales were up 3.4% vs. 2Q13. Macy's backed its fiscal year 2014 EPS guidance of $4.40-$4.50. The consensus for FY14 EPS at that time was $4.47. The retailer said its expectations for the second half of 2014 were "on track," with guidance for comparable store growth of 2%-3%. However, Macy's predicted FY14 SSS up 1.5%-2%, with FY14 comparable sales together with comparable sales of departments licensed to third parties up 2%-2.5%; previous guidance was for FY SSS up 2.5%-3%. NEWS: On its last earnings conference call, Macy's forecast fall season EPS of $3.04-$3.14 and said it expected Q3 SSS would be lower than fourth quarter SSS. The retailer also forecast second half total sales growth approximately 30 basis points lower than comp growth and gross margin rate "flat to down slightly" for the year. During the quarter, Macy's reached a resolution with the New York State Office of the Attorney General related to allegations of racial profiling in its New York stores. The retailer said it will launch same-day delivery this fall and announced plans to hire 86,000 seasonal associates for the 2014 holiday season. CNN said Macy's will open at 6pm on Thanksgiving Day. STREET RESEARCH: Cleveland Research said Macy's trends decelerated at the back-end of Q3, likely pressuring Q3 comp performance. The analyst expects promotional activity to pick-up in Q4 in order to capture share and traffic. ITG Research said in October that Macy's Q3 revenues were tracking to $6.25B. Northcoast upgraded Macy's to Buy from Neutral on November 5. PRICE ACTION: Over the last three months, Macy's shares are down 2%. The stock is trading down fractionally to $58.92 ahead of tomorrow's report.
12:00 EDTICPTIntercept results said to be rejected by New England Journal, Bloomberg says
Subscribe for More Information
08:59 EDTMMacy's trends softened in back-end of Q3, says Cleveland Research
Cleveland Research said Macy's trends decelerated at the back-end of Q3, likely pressuring Q3 comp performance. The analyst expects promotional activity to pick-up in Q4 in order to capture share and traffic, and to offset the challenging Q3 performance. Shares are Buy rated.
07:49 EDTANFBofA/Merrill retail and consumer analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
12:36 EDTANFAbercrombie, American Eagle sink after analyst downgrades
Shares of specialty teen apparel retailers Abercrombie & Fitch (ANF) and American Eagle Outfitters (AEO) are falling after a number of analysts issued negative notes on the companies. WHAT'S NEW: Oppenheimer analyst Anna Andreeva downgraded Abercrombie & Fitch to Perform from Outperform. The company's earnings outlook has become less clear as its U.S. brand has not yet become popular, and retail brand turnarounds usually take awhile, Oppenheimer analyst Anna Andreeva wrote in a note to investors. Additionally, Abercrombie's international business, which has deteriorated further this year, faces "mounting uncertainty, the analyst stated. The analyst slashed her price target on the name to $30 from $50. Meanwhile, Barclays analyst Matthew McClintock downgraded American Eagle Outfitters to Equal Weight from Overweight. McClintock has become more pessimistic about the outlook for American Eagle's comparative store sales in the second half of 2014, given recent data points from a number of retailers, including Abercrombie & Fitch, Kohl's (KSS), Wal-Mart (WMT), J.C. Penney (JCP), and Ann Inc. (ANN). The analyst said he saw no reason why American Eagle should significantly outperform the overall apparel sector. McClintock cut his price target on the name to $11 from $15. Meanwhile, the analyst lowered his rating on the Softline Retail sector to Negative from Positive, as he believes that the sector, which includes companies that sell products like apparel, towels, and jewelry - is facing structural difficulties that are likely to persist for the next several years. Separately, research firm Janney Capital downgraded Abercrombie to Neutral from Buy in a note to investors today. PRICE ACTION: In early afternoon trading, Abercrombie & Fitch sank 3.5% to $28.50 and American Eagle dropped 4% to $12.40.
10:04 EDTANFOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded at Oppenheimer... American Eagle (AEO) downgraded to Neutral from Buy at B. Riley... BP (BP) downgraded to Neutral from Overweight at JPMorgan... Callon Petroleum (CPE) downgraded to Neutral from Buy at SunTrust... EP Energy (EPE) downgraded to Hold from Buy at Deutsche Bank... Eaton Vance (EV) downgraded at Sterne Agee... Ecopetrol (EC) downgraded to Underperform from Sector Perform at RBC Capital... General Mills (GIS) downgraded to Sector Perform from Outperform at RBC Capital... Genworth (GNW) downgraded to Market Perform from Outperform at Keefe Bruyette... MasTec (MTZ) downgraded to Hold from Buy at BB&T... Ocean Rig UDW (ORIG) downgraded to Neutral from Buy at Guggenheim... Performant Financial (PFMT) downgraded at Morgan Stanley... Petrobras (PBR) downgraded to Market Perform from Outperform at Cowen... R.R. Donnelley (RRD) downgraded to Hold from Buy at Benchmark Co.... Rex Energy (REXX) downgraded to Market Perform from Outperform at BMO Capital... Salix (SLXP) downgraded to Neutral from Buy at Mizuho... Siemens (SIEGY) downgraded to Neutral from Overweight at JPMorgan... Solazyme (SZYM) downgraded to Equal Weight from Overweight at Morgan Stanley... Stonegate Mortgage (SGM) downgraded to Market Perform at FBR Capital... Syngenta (SYT) downgraded to Neutral from Overweight at HSBC... ViaSat (VSAT) downgraded to Hold from Buy at Needham... Vistaprint (VPRT) downgraded to Neutral from Buy at SunTrust... Walter Investment (WAC) downgraded at Sterne Agee... WesBanco (WSBC) downgraded to Market Perform from Outperform at Keefe Bruyette... Whiting USA Trust II (WHZ) downgraded to Underperform at Raymond James... Wipro (WIT) downgraded to Sell from Buy at UBS... XOMA (XOMA) downgraded to Neutral from Buy at Ladenburg... Yanzhou Coal (YZC) downgraded to Sell from Hold at Deutsche Bank.
10:04 EDTTGTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:08 EDTSHLDSears announces plans for mixed-use development in Aventura
Subscribe for More Information
08:36 EDTICPTIntercept price target lowered to $125 from $172 at FBR Capital
FBR Capital lowered its price target for Intercept shares to $125 saying its talks with experts and cardiologists indicate the company's OCA drug is unlikely to be a "silver bullet" for the treatment of nonalcoholic steatohepatitis. FBR notes that while OCA appears to improve the liver, the drug worsens many of the other derangements like lipid and glucose homeostasis. FBR decreased the probability of success in NASH to 55% from 60%, and lowered its peak OCA sales estimate to $5.2B. It keeps an Underperform rating on Intercept shares.
08:08 EDTTGTTarget upgraded at Stifel
Subscribe for More Information
07:50 EDTANFAbercrombie & Fitch downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded to Abercrombie & Fitch Perform from Outperform. The firm downgraded the stock, citing lack of visibility, following the company's negative preannouncement. Target to $30 from $50.
07:12 EDTMCA Technologies to hold a conference
CA World 2014 is being held in Las Vegas on November 9-12.
07:11 EDTSHLDOpen Mobile Media to hold a summit
Subscribe for More Information
07:05 EDTSHLDMarket too upbeat on Sears report, Reuters columnist says
Subscribe for More Information
06:34 EDTANFAbercrombie & Fitch downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
05:54 EDTTGTTarget upgraded to Buy from Hold at Stifel
Subscribe for More Information
05:48 EDTANFU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
05:40 EDTANFAbercrombie & Fitch downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
November 9, 2014
11:56 EDTICPTIntercept announces additional data for OCA in primary biliary cirrhosis
Intercept Pharmaceuticals announced new analyses of data from clinical trials on obeticholic acid, OCA, in patients with primary biliary cirrhosis, PBC. Six posters, including posters with new analyses of data from POISE the first Phase 3 trial in PBC in two decades are being presented at today's poster session at the American Association for the Study of Liver Disease, AASLD, Annual Meeting. OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor, FXR, in development for PBC, nonalcoholic steatohepatitis, NASH, primary sclerosing cholangitis, PSC, and other chronic liver diseases.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use